European Headache Alliance

Tag Archives: treatment

“Green light” to Lilly’s monoclonal antibody to migraine

Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab ( Emgality ) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month . Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes…
Read More

100 Million Neurons Found Outside The Brain

Trupti Gokani, MD is a neurologist and author of The Mysterious Mind. She practices a blend of Western and Eastern medicine which focuses on the root cause and holistic treatment of a patient, combined with functional neurology. Dr. Gokani told us about the significance of the gut-brain connection in her recent interview. As neurologists, Dr.…
Read More

Estrogen may explain why women suffer more often migraines

Spanish researchers have discovered that the role of this sex hormone around the trigeminal nerve could be key in migraine episodes, which could explain why woman suffer from them more often.  Sex hormones could play a key role in the onset of migraine episodes, according to a study published today by the team of Antonio…
Read More

New Aimovig Medication Approved

Novartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its- kind treatment specifically designed for migraine prevention Jul 30, 2018 Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first…
Read More

Why are migraine patients skipping effective behavioral treatments?

Effective behavioral treatments for migraine are being eschewed by a significant number of sufferers, according to a new study led by headache researchers at NYU School of Medicine. Researchers found that about half of migraine patients who were referred by a headache center for specific behavioral treatment did not follow through with therapy. This occurred…
Read More

Novartis’ Migraine prevention therapy is closer to being approved

Friday, June 1, 2018, at 15:45 Novartis has announced that the European Medicines Agency (EMA) Committee on Human Use Medicines (CHMP) has recommended Aimovig (erenumab) approval to prevent migraine in adults suffering at least 4 days of migraine per month. The World Health Organization (WHO) has mentioned migraine as one of the top ten causes…
Read More